inclusion criteria: 1. patient who agrees to participate in the study by signing the informed consent. 2. men and women (non-pregnant) aged ≥18 years. 3. covid-19 infection confirmed by pcr obtained from nasopharyngeal exudate or sample from the lower respiratory tract. 4. patients who require hospitalization for covid-19. 5. symptom onset at most within 10 days prior to study inclusion. 6. men and women with reproductive capacity should agree to use highly effective contraceptive methods during their participation in the study and in the 6 months following the last administration of plitidepsin. 7. in addition, women participating in the study with reproductive ability must have a negative pregnancy test at enrollment.

inclusion criteria: 1. patient who agrees to participate in the study by signing the informed consent. 2. men and women (non-pregnant) aged ≥18 years. 3. covid-19 infection confirmed by pcr obtained from nasopharyngeal exudate or sample from the lower respiratory tract. 4. patients who require hospitalization for covid-19. 5. symptom onset at most within 10 days prior to study inclusion. 6. men and women with reproductive capacity should agree to use highly effective contraceptive methods during their participation in the study and in the 6 months following the last administration of plitidepsin. 7. in addition, women participating in the study with reproductive ability must have a negative pregnancy test at enrollment.

inclusion criteria: patient who agrees to participate in the study by signing the informed consent. men and women (non-pregnant) aged ≥18 years. covid-19 infection confirmed by pcr obtained from nasopharyngeal exudate or sample from the lower respiratory tract. patients who require hospitalization for covid-19. symptom onset at most within 10 days prior to study inclusion. men and women with reproductive capacity should agree to use highly effective contraceptive methods during their participation in the study and in the 6 months following the last administration of plitidepsin. in addition, women participating in the study with reproductive ability must have a negative pregnancy test at enrollment.

inclusion criteria: patient who agrees to participate in the study by signing the informed consent. men and women (non-pregnant) aged ≥18 years. covid-19 infection confirmed by pcr obtained from nasopharyngeal exudate or sample from the lower respiratory tract. patients who require hospitalization for covid-19. symptom onset at most within 10 days prior to study inclusion. men and women with reproductive capacity should agree to use highly effective contraceptive methods during their participation in the study and in the 6 months following the last administration of plitidepsin. in addition, women participating in the study with reproductive ability must have a negative pregnancy test at enrollment.

inclusion criteria: 1. patient who agrees to participate in the study by signing the informed consent. 2. men and women (non-pregnant) aged ≥18 years. 3. covid-19 infection confirmed by pcr obtained from nasopharyngeal exudate or sample from the lower respiratory tract. 4. patients who require hospitalization for covid-19. 5. symptom onset at most within 10 days prior to study inclusion. 6. men and women with reproductive capacity should agree to use highly effective contraceptive methods during their participation in the study and in the 6 months following the last administration of plitidepsin. 7. in addition, women participating in the study with reproductive ability must have a negative pregnancy test at enrollment.

inclusion criteria: 1. patient who agrees to participate in the study by signing the informed consent. 2. men and women (non-pregnant) aged ≥18 years. 3. covid-19 infection confirmed by pcr obtained from nasopharyngeal exudate or sample from the lower respiratory tract. 4. patients who require hospitalization for covid-19. 5. symptom onset at most within 10 days prior to study inclusion. 6. men and women with reproductive capacity should agree to use highly effective contraceptive methods during their participation in the study and in the 6 months following the last administration of plitidepsin. 7. in addition, women participating in the study with reproductive ability must have a negative pregnancy test at enrollment.